NMS·Healthcare·$1.6B·#184 / 520 in Healthcare
GLUE Monte Rosa Therapeutics, Inc.
55SPECULATIVE
CATEGORY BREAKDOWN
GROWTH85
QUALITY20
STABILITY96
VALUATION35
GOVERNANCE3
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
+63.5%
85
> 50% strong
Gross Margin
Revenue retained after direct costs
N/A
0
> 50% strong
Cash Runway
Months of cash at current burn rate
68 months
100
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
16.8%
87
< 25% strong
Price / Sales
Market cap relative to trailing revenue
12.7x
35
< 3x strong
Rule of 40
Growth rate plus operating margin
20
50
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
0.6%
5
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+30.1%
0
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE GLUE WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when GLUE's score changes by 5+ points.
DATA INFO
Last updated: May 4, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.